ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0467

All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study

Jacob Sode1, Jens Rathmann1, Anna Wilding2, Carl Turesson3 and Aladdin Mohammad1, 1Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, 2Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Cohort Study, giant cell arteritis, Mortality, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Most previous studies have demonstrated a similar overall survival in patients with GCA compared to the background population. However, we have previously reported an increased mortality during the first two years after diagnosis in patients diagnosed through 2010, in particular among those aged < 70 years. Up till now, no data on cause of death has been presented from our area. Our aim was to investigate all-cause and cause-specific mortality in a large population-based cohort of patients with temporal artery biopsy-proven GCA (TAB+GCA) compared to matched controls from the general population.

Methods: All patients diagnosed with TAB+GCA between 1997 and 2019 in the region were included in this study. For each patient with GCA, 20 controls were selected from the background population matched for age, sex, and place of residency. Controls with a vasculitis diagnosis were excluded. Data on all-cause mortality were extracted from the national cause of death register. Time of follow up was calculated in person-years (py) from the date of GCA diagnosis for cases (index-date for controls) to death or end of study (December 31, 2020). Rates of death for patients and controls were calculated and rate ratios (death rate in GCA: controls) were estimated. Survival was also studied using the Kaplan-Meier curves. Differences between groups were studied using the Log-Rank test. Primary cause of death was grouped into the following categories: vasculitis, infection, cardiovascular, cancer and other.

Results: A total of 1,354 patients (71% female) with TAB+GCA and 26,406 controls were included. The mean age at diagnosis was 75.2 (SD 7.9) for all patients, 75.5 (SD 7.6) for females vs. 74.5 (SD 8.4) for males. Seven hundred nineteen patients with GCA died during 11,018 py of follow up vs. 12,960 controls during 222,143 py of follow up. The rate of death was 65.3/1,000 py in GCA patients vs. 58.3/1,000 py in controls resulting in a rate ratio of 1.1 (95% CI 1.0-1.2). During the first year after GCA diagnosis (index-date) the rate ratio was 1.5 (95% CI 1.2-1.9). The death rate and rate ratios for different time periods after GCA diagnosis (index date) are summarized in Table 1. The 1, 5 and 10-years cumulative survival was 94%, 79% and 56% in patients and 96%, 80% and 58% in controls (p = < 0.01), Figure 1. During the first year from diagnosis, the main cause of death was cardiovascular disease (Table 2). By contrast, a smaller proportion of patients with GCA died from cancer compared to controls.

Conclusion: In this study, mortality in patients with GCA was increased with 50% compared to matched controls during first year of follow up after diagnosis. The main cause of this early excess mortality appears to be cardiovascular disease.

Supporting image 1

Table 1. Rate of death (per 1,000 years of follow up) in patients and matched controls

Supporting image 2

Supporting image 3

Figure 1. Kaplan-Meier plot showing 10-year mortality in patients with GCA compared to matched controls


Disclosures: J. Sode, None; J. Rathmann, None; A. Wilding, None; C. Turesson, AbbVie/Abbott, Nordic Drugs, Bristol-Myers Squibb(BMS); A. Mohammad, None.

To cite this abstract in AMA style:

Sode J, Rathmann J, Wilding A, Turesson C, Mohammad A. All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-based Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/all-cause-and-cause-specific-mortality-in-giant-cell-arteritis-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/all-cause-and-cause-specific-mortality-in-giant-cell-arteritis-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology